Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 462 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone 8 mg Clear all
Completed Phase 3 Interventional Results available

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 5, 2026, 4:41 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

NCT00801138
View directory record Official record
Conditions
Anesthesia, Local, Shoulder Surgery
Interventions
saline, Dexamethasone, ropivacaine, Bupivacaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects

NCT01980589
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Encinitas, California • West Hollywood, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00005596
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

NCT00617591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Pegylated Liposomal Doxorubicin (PLD), Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 5, 2026, 4:41 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 5, 2026, 4:41 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01029054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, lenalidomide plus dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

NCT01488279
View directory record Official record
Conditions
Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions
Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

NCT01692197
View directory record Official record
Conditions
Leukemia
Interventions
E7070, Idarubicin, Cytarabine, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

NCT01850524
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Placebo, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
78
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Dyspnea Study

NCT01670097
View directory record Official record
Conditions
Advanced Cancers, Hematologic Disorder, Solid Tumors
Interventions
Dexamethasone, Placebo, Questionnaires, Spirometer, Phone Calls
Drug · Behavioral · Device + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

NCT00450801
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Methotrexate, Thalidomide, Vincristine, Mesna, Filgrastim (G-CSF), Granisetron, Decadron
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 5, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

NCT03871829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg, Dara-SC 1800 mg, Dexamethasone 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Gilbert, Arizona • Tucson, Arizona • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 3 Interventional

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

NCT00002548
View directory record Official record
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

UARK 2003-33, Total Therapy III

NCT00081939
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Results available

Study of Proton Therapy in Adjuvant Pancreatic Cancer

NCT03885284
View directory record Official record
Conditions
Resected Pancreatic Adenocarcinoma
Interventions
mFOLFIRINOX, Proton beam radiation
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 5, 2026, 4:41 PM EDT
Withdrawn Phase 2 Interventional

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

NCT02578121
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

NCT01054144
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Prednisone, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 5, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 4 Interventional

Methylprednisolone Taper After Total Knee Replacement

NCT05859269
View directory record Official record
Conditions
Knee Arthritis
Interventions
Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 5, 2026, 4:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00144963
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Vincristine Sulfate Liposomes Injection, Dexamethasone
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 5, 2026, 4:41 PM EDT
Withdrawn Phase 3 Interventional

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03334487
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Dexamethasone, Rovalpituzumab tesirine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
27
States / cities
Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 5, 2026, 4:41 PM EDT